Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?"

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: Jessie.Torgersen@pennmedicine.upenn.edu.
² VA Connecticut Healthcare System, West Haven, CT, USA; Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
³ Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Comment

Jessie Torgersen et al. J Hepatol. 2022 Jul.

. 2022 Jul;77(1):258-259.

doi: 10.1016/j.jhep.2022.02.025. Epub 2022 Mar 10.

¹ Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: Jessie.Torgersen@pennmedicine.upenn.edu.
² VA Connecticut Healthcare System, West Haven, CT, USA; Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
³ Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

No abstract available

Conflict of interest statement

Conflict of interest All authors declare no conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd. Torgersen J, et al. J Hepatol. 2021 Dec;75(6):1312-1322. doi: 10.1016/j.jhep.2021.07.021. Epub 2021 Jul 29. J Hepatol. 2021. PMID: 34333102 Free PMC article.
Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?
Wong YJ, Nguyen MH. Wong YJ, et al. J Hepatol. 2022 Jul;77(1):257-258. doi: 10.1016/j.jhep.2021.12.037. Epub 2022 Jan 21. J Hepatol. 2022. PMID: 35074472 No abstract available.